On April 19, 2017, Ma, Xiaodong; Ge, Yang; Zhang, Jianbin; Liu, He; Huang, Shanshan; Li, Zhen; Wang, Changyuan; Liu, Zhihao; Peng, Jinyong; Liu, Kexin published a patent.Electric Literature of 16230-24-3 The title of the patent was Diphenylamine pyrimidine compounds as BTK and/or JAK3 inhibitors and their preparation. And the patent contained the following:
The invention relates to diphenylamine pyrimidine compounds of formula I as BTK and/or JAK3 inhibitors and their preparation Compounds I, wherein X is H, Cl, F, NO2, or CF3; Y is O or NH; L is COCH2 or CH2CO; R1 is H, Me, OMe, or Cl; R2 is diethylamino, dibutylamino, etc.; their pharmaceutically acceptable salts, are claimed. The invention compounds can be used for treating tumor disease by suppressing Bruton’s tyrosyl protein kinase BTK and/or Janus tyrosine kinase JAK3, especially for the treatment of Burkitt’s lymphoma, diffuse large B cell lymphoid tumor, follicular lymphoma or chronic lymphocytic leukemia. The experimental process involved the reaction of N-(3-Aminophenyl)acrylamide(cas: 16230-24-3).Electric Literature of 16230-24-3
The Article related to diphenylamine pyrimidine preparation btk jak3 inhibitor treatment cancer, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Electric Literature of 16230-24-3
Referemce:
Amide – Wikipedia,
Amide – an overview | ScienceDirect Topics